Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

growth agriculture pty ltd - modified polydimethylsiloxane - liquid - modified polydimethylsiloxane emulsifiers & surfactants-noni active 1064.0 g/l - wetting agent - foliar micro-nutrients | fungicide additive | herbicide additive | insecticide additive | miticide additive | activator | additi - blackberry - rubus spp. | bracken | furze or gorse | lantana - lantana camara | st john's wort | sweet briar or wild rose | austral bracken | common bracken | common lantana | h. perforatum var. angustifoli | kamara lantana | sweetbriar | wild rose

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - modified polydimethylsiloxane - liquid - modified polydimethylsiloxane emulsifiers & surfactants-noni active 1000.0 g/l - adjuvant - foliar micro-nutrients | fungicide additive | herbicide additive | insecticide additive | miticide additive | pesticide additive - penetrating surfactant | spreading agent | wetting agent (use as directed) | improve penetrating properties

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 460 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 345 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; iron oxide black; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 230 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 172.5 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 57.5 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; iron oxide black; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.